Show simple item record

FieldValueLanguage
dc.contributor.authorDrabarek, Dorothy
dc.contributor.authorHabgood, Emily
dc.contributor.authorJanda, Monika
dc.contributor.authorHersch, Jolyn
dc.contributor.authorAckermann, Deonna
dc.contributor.authorLow, Don
dc.contributor.authorLow, Cynthia
dc.contributor.authorMorton, Rachael L
dc.contributor.authorDieng, Mbathio
dc.contributor.authorCust, Anne E
dc.contributor.authorMorgan, Adelaide
dc.contributor.authorSmith, Elloise
dc.contributor.authorBell, Katy L J
dc.date.accessioned2023-03-20T03:27:10Z
dc.date.available2023-03-20T03:27:10Z
dc.date.issued2022en_AU
dc.identifier.urihttps://hdl.handle.net/2123/30246
dc.description.abstractBackground: Current clinician-led melanoma surveillance models require frequent routinely scheduled clinic visits, with associated travel, cost, and time burden for patients. Patient-led surveillance is a new model of follow-up care that could reduce health care use such as clinic visits and medical procedures and their associated costs, increase access to care, and promote early diagnosis of a subsequent new melanoma after treatment of a primary melanoma. Understanding patient experiences may allow improvements in implementation. Objective: This study aims to explore patients’ experiences and perceptions of patient-led surveillance during the 6 months of participation in the MEL-SELF pilot randomized controlled trial. Patient-led surveillance comprised regular skin self-examination, use of a mobile dermatoscope to image lesions of concern, and a smartphone app to track and send images to a teledermatologist for review, in addition to usual care. Methods: Semistructured interviews were conducted with patients previously treated for melanoma localized to the skin in New South Wales, Australia, who were randomized to the patient-led surveillance (intervention group) in the trial. Thematic analysis was used to analyze the data with reference to the technology acceptance model. Results: We interviewed 20 patients (n=8, 40% women and n=12, 60% men; median age 62 years). Patients who were more adherent experienced benefits such as increased awareness of their skin and improved skin self-examination practice, early detection of melanomas, and opportunities to be proactive in managing their clinical follow-up. Most participants experienced difficulty in obtaining clear images and technical problems with the app. These barriers were overcome or persevered by participants with previous experience with digital technology and with effective help from a skin check partner (such as a spouse, sibling, or friend). Having too many or too few moles decreased perceived usefulness. Conclusions: Patients with melanoma are receptive to and experience benefits from patient-led surveillance using teledermoscopy. Increased provision of training and technical support to patients and their skin check partners may help to realize the full potential benefits of this new model of melanoma surveillance.en_AU
dc.language.isoenen_AU
dc.publisherJMIR Dermatologyen_AU
dc.rightsCreative Commons Attribution 4.0en_AU
dc.subjectmelanomaen_AU
dc.subjectself-surveillanceen_AU
dc.subjectdigital technologiesen_AU
dc.subjectteledermoscopyen_AU
dc.subjectteledermatologyen_AU
dc.subjectmHealthen_AU
dc.subjectmobile phoneen_AU
dc.titleExperiences of Patient-Led Surveillance, Including Patient-Performed Teledermoscopy, in the MEL-SELF Pilot Randomized Controlled Trial: Qualitative Interview Studyen_AU
dc.typeArticleen_AU
dc.identifier.doidoi:10.2196/35916
dc.type.pubtypePublisher's versionen_AU
usyd.facultyFaculty of Medicine and Healthen_AU
usyd.departmentNHMRC Clinical Trials Centreen_AU
workflow.metadata.onlyNoen_AU


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.